Prime Medicine, Inc. (PRME)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$4.45-10.46%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · PRME
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 492.8% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-05 · Compared with 117 industry peers
PRME — earnings in line
Dated 2026-08-06
of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Why it matters: The first patient enrollment would move PM577a from study setup into human testing. Initial data are planned for 2027.
Supportive ifThe company reports that the first patient joined the global Phase 1/2 PM577a study in the second half of 2026.
Worry ifThe company reports that study startup is delayed, or no patients are enrolled by year-end 2026.
Why it matters: A filing would keep the AATD program on its stated path toward human testing. The company links PM647 and PM577a data to 2027.
Supportive ifThe company announces an IND or CTA submission for PM647 by Sept. 30, 2026.
Worry ifThe company reports that the PM647 filing missed Q3 2026 or has been delayed beyond its stated timeline.
Why it matters: A clear FDA path would support the planned BLA filing in the first half of 2027. A changed plan could delay the next major step.
Supportive ifThe company reports FDA alignment on a BLA path and keeps the filing window in the first half of 2027.
Worry ifThe company reports that FDA discussions require more work or push the planned BLA filing past the first half of 2027.
Why it matters: Management has set near-term milestones for both liver programs. The update can show whether study startup and filing plans remain on track.
Watch forOn Nov. 6, the company reports PM577a enrollment progress and confirms the PM647 IND or CTA was filed in Q3.
Also watch forOn Nov. 6, the company reports PM577a startup delays or says the PM647 filing missed Q3.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$337 on $10,000 · ±3.4% | How much price usually moves either way. |
| Bad day | $878 loss on $10,000 · 8.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,225 loss on $10,000 · 42.3% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.